About NextCell

NextCell is a Swedish biopharmaceutical company headquartered in Huddinge, adjacent to the Karolinska University Hospital. NextCell operates in two business areas – Cellaviva and ProTrans – with the shared core being stem and stromal cells derived from the umbilical cord.

Business concept

NextCell's business concept is to develop and commercialize mesenchymal stromal cell products based on the company's patented selection algorithm, primarily for the treatment of autoimmune type 1 diabetes, alongside other types of autoimmune and inflammatory diseases.

NextCell's pivotal drug candidate is ProTrans, developed initially for the treatment of type 1 diabetes. Both safety and efficacy in preserving the patients' ability to produce their own insulin have been demonstrated in clinical drug trials.

Cellaviva is the largest private stem cell bank in Scandinavia. Through Cellaviva, expectant parents are provided with the opportunity to preserve and store their newborn child's stem cells for potential future medical needs of both the child and the family.

Vision

Pioneering cell therapy development for thetreatment of autoimmune and inflammatorydisorders.

‍

Mission

Lead the way in the development of next generation off-the-shelf cell therapies for treatment of autoimmune and inflammatory disorders.

Strategy

Short term

To show the safety and efficacy of ProTrans in children, adolescents and adults newly diagnosed with type 1 diabetes
To secure production facility capabilities in several sites
To secure the regulatory pathways for marketing authorisation approval

‍Long term

To take ProTrans to market for the indication of type 1 diabetes in a patient populationthat includes children, adolescents, and adults
To continue to build the platform technology to find new treatments for other inflammatory disorders that are currently lacking effective treatments with safety and efficacy

History

NextCell was founded in 2014 by CEO Dr. Mathias Svahn, two current board members; Professor Edvard Smith and Hans-Peter Ekre, as well as Dr. Lena Degling Wilkingsson. The company was originally named Cellaviva AB. In 2016, a strategic decision was made to expand the operation and also conduct drug development and stromal cell research. At this point the company changed its name to NextCell Pharma AB.

Organisation

Management

Mathias Svahn

CEO

Born in 1976. Ph.D. and co-founder, background as scientific manager at KI and country medical manager at Roche. Joined NextCell Pharma in 2015. Holdings in NextCell Pharma as of March 28, 2024: 507 261 shares.

Patrik Fagerholm

CFO

Born in 1967. M. Sc. in Finance and Business Administration. Responsible for the financial operations. Joined NextCell Pharma in 2021. Holdings as of March 28, 2024: 16 600 shares.

Lindsay Davies

CSO

Born in 1979. PhD with a long experience in stromal cell biology and development of cell therapies. In the role as CSO, Davies is responsible for the existing research portfolio as well as the development of new clinical treatments. Lindsay Davies joined NextCell Pharma in 2020. Holdings in NextCell Pharma as of March 28, 2024: 0 shares.

Edvard Smith

Medical director

Born in 1951. MD, professor, co-founder and medically responsible for NextCell Pharma AB and Cellaviva. Professor of Molecular Genetics at the Department of Laboratory Medicine at Karolinska Institutet and Karolinska University Hospital, Huddinge. His research has resulted in the identification of several disease genes and to new treatments. Edvard Smith joined NextCell Pharma in 2014. Holdings in NextCell Pharma as of March 28, 2024: 144 775 shares.

Sofie Falk Jansson

Head of Cellaviva

Born in 1986. Experienced marketeer within business to consumer. Joined NextCell Pharma in 2018. Holdings as of March 28, 2024: 5 066 shares.

Sofia Sisay

Head of Clinical Trials

Born in 1981, Sofia Sisay possesses a PhD in Neuroscience, accompanied by a significant track record in orchestrating clinical studies and projects across both academic and industrial domains. In her role as Clinical Trial Manager, Sisay holds responsibility for the oversight of all ongoing clinical trials and has been entrusted with project leadership since the inception of NextCell's inaugural clinical trial. Sofia Sisay has been member of the NextCell Pharma team since the 2022. Holdings in NextCell Pharma as of March 28, 2024: 0 shares.

Karin Gillner

Head of Quality Assurance

Born in 1978, Karin holds a PhD in human embryonic stem cell biology, with a strong background in basic research and method development. She has experiencein project management, quality assurance, and regulatory affairs across both academic and industrial spheres. Joining NextCell Pharma AB at the beginning of 2023, Karin is responsible for the establishment of the GMP production quality system. Holdings in NextCell Pharma as of March 28, 2024: 2 915 shares.

Tacha Zi Plym Forshell

Head of GMP-facility

Born in 1977, Tacha Zi Plym Forshell holds a PhD in Molecular Biology, with an extensive background in cell therapy development and GMP production within ATMP. Tacha Zi Plym Forshell has been working for NextCell Pharma since 2019. Holdings in NextCell Pharma as of March 28, 2024: 0 shares.

Board

Anders Essen-Möller

Chairman of the board

Born in 1941. Independent of the Company, principal owner. Board member and founder of Diamyd Medical AB and Synectics Medical AB. Board member since 2014 and Chairman of the Board since 2018. Holdings in NextCell Pharma as of March 28, 2024: 2 558 005 shares.

Camilla Myhre Sandberg

Board member

Born in 1967. Independent of the Company and its principal owners. Board member with a marketing background in cell therapy and regenerative medicine, CEO at Miris Holding AB. Board member since 2017. Holdings in NextCell Pharma as of March 28, 2024: 0 shares.

Edvard Smith

Board member

Born in 1951. Independent of the Company´s principal owner. Member of the Management as Medical Director. Professor of Molecular Genetics at the Department of Laboratory Medicine at Karolinska Institutet and Karolinska University Hospital, Huddinge. His research has resulted in the identification of several disease genes and to new treatments. Board member since 2014. Holdings in NextCell Pharma as of March 28, 2024: 144 775 shares.

Hans-Peter Ekre

Board member

Born in 1950. Independent of the Company and its principal owners. Background as investment manager at Karolinska Development and R&D manager at Pharmacia, Astra and Biotech companies. Board member since 2014. Holdings in NextCell Pharma as of March 28, 2024: 139 970 shares.

Medical Advisers

Edvard Smith

MD

MD, professor, co-founder and medically responsible for NextCell Pharma AB and Cellaviva since 2014. Professor of Molecular Genetics at the Department of Laboratory Medicine at Karolinska Institutet and Karolinska University Hospital, Huddinge. His research has resulted in the identification of several disease genes and to new treatments.

Gunvor Ekman-Ordeberg

MD

Professor in Obstetrics and gynecology at Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.

Per-Ola Carlsson

MD

Professor in Medical Cell biology and experimental endocrinology at the Department of Medical Sciences, Transplantation and Regenerative medicine, Akademiska University Hospital, Uppsala, Sweden.

Timo Otonkoski

MD

Professor of Medical Stem Cell Research, Children’s Hospital and Biomedicum Stem Cell Center, Program of Molecular Neurology, University of Helsinki, Helsinki, Finland

Xiao-Dong Chen

MD

Professor and VA Research Health Scientist; Chief, Regenerative Medicine Program; Department of Physiology, University of Texas Health Science Center, San Antonio, USA

Company Structure

NextCell Pharma AB is not part of a group. The company owns 8.5% of the shares in FamicordTx. The company has one daughter company, Qvance AB and one auxiliary company; Cellaviva.